Ongoing concerns about Avandia (rosiglitazone)
April 2010
Ongoing concerns about Avandia (rosiglitazone) will prompt more safety review by FDA....
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote